// App-Quantinova.ai

264 : Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis

Researchers

Presenter

  • Paul Emery

Principal Investigators

  • Xenofon Baraliakos

  • Jrgen Braun

  • Atul Deodhar

  • Denis Poddubnyy

  • Eumorphia-Maria Delicha

  • Zsolt Talloczy

  • Brian Porter

Medical Centers

  • Institute of Rheumatic and Musculoskeletal Medicine, Biomedical Research Centre LTHT, University of Leeds, Leeds, UNITED KINGDOM

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

  • Department of Neurosurgery, Oregon Health and Science University, Portland, OR

  • n/a, Charité–Universitätsmedizin Berlin, Berlin, GERMANY

  • Immunology, Hepatology, and Dermatology Development Unit, Novartis Pharma AG, Basel, SWITZERLAND

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

Locations

  • United Kingdom

  • Germany

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT01863732

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved